Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication
- PMID: 19375110
- DOI: 10.1016/j.juro.2009.02.028
Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication
Abstract
Purpose: We assessed the effect of tolterodine extended release plus behavioral intervention on treatment satisfaction and bladder diary variables in patients with overactive bladder who had been previously treated and were dissatisfied with tolterodine or other antimuscarinics.
Materials and methods: This 16-week, multicenter, open label study included eligible patients 18 years old or older who reported overactive bladder symptoms 3 months or greater in duration, 8 or greater micturitions and 2 or greater urgency related micturitions per 24 hours, and 1 or greater urgency urinary incontinence episodes in a 5-day bladder diary at baseline as well as dissatisfaction with prior antimuscarinic medication. Patients received tolterodine extended release plus self-administered behavioral intervention, consisting of an educational pamphlet with verbal reinforcement, for 8 weeks. Satisfied patients continued with this therapy and dissatisfied patients received tolterodine extended release plus individualized behavioral intervention, consisting of in-depth interaction with a clinician to refine behavioral techniques, for 8 weeks thereafter. Patients rated treatment satisfaction at weeks 8 and 16, and completed a 5-day bladder diary at weeks 4, 8, 12 and 16, respectively.
Results: At weeks 8 and 16, 346 and 357 patients or 91% of the total cohort reported being at least a little satisfied with tolterodine extended release plus behavioral intervention, including 201 (53%) and 252 (64%), respectively, who were very satisfied. Of the 33 patients who were dissatisfied at week 8, 25 (76%) reported treatment satisfaction at week 16 after individualized behavioral intervention. Compared with baseline all bladder diary variables were significantly improved by week 4 (p <0.0001). Patients who were dissatisfied with prior tolterodine or other antimuscarinic treatment reported similar results.
Conclusions: Tolterodine extended release plus behavioral intervention resulted in high treatment satisfaction and improved bladder diary variables in patients who had previously been treated and were dissatisfied with tolterodine or other antimuscarinics.
Similar articles
-
Effects of combined behavioral intervention and tolterodine on patient-reported outcomes.Can J Urol. 2010 Aug;17(4):5283-90. Can J Urol. 2010. PMID: 20735908 Clinical Trial.
-
Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.Clin Ther. 2008 Oct;30(10):1766-81. doi: 10.1016/j.clinthera.2008.10.011. Clin Ther. 2008. PMID: 19014833 Clinical Trial.
-
Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.BJU Int. 2010 Jan;105(1):58-66. doi: 10.1111/j.1464-410X.2009.09086.x. BJU Int. 2010. PMID: 20132103 Clinical Trial.
-
Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder.Curr Med Res Opin. 2007 Aug;23(8):1903-12. doi: 10.1185/030079907X210598. Curr Med Res Opin. 2007. PMID: 17610806 Review.
-
Tolterodine for treatment of overactive bladder.Urol Clin North Am. 2006 Nov;33(4):447-53, viii. doi: 10.1016/j.ucl.2006.06.004. Urol Clin North Am. 2006. PMID: 17011380 Review.
Cited by
-
Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron 50 mg in Sexually Active Men With Bothersome Overactive Bladder Symptoms - A Multicenter, Randomized Study.Int Neurourol J. 2023 Sep;27(3):182-191. doi: 10.5213/inj.2346148.074. Epub 2023 Sep 30. Int Neurourol J. 2023. PMID: 37798885 Free PMC article.
-
Efficacy of Yun-Type Optimized Pelvic Floor Training Therapy for Middle-Aged Women With Severe Overactive Bladder: A Randomized Clinical Trial.Front Surg. 2021 Jul 14;8:670123. doi: 10.3389/fsurg.2021.670123. eCollection 2021. Front Surg. 2021. PMID: 34336915 Free PMC article.
-
Neuromodulation for overactive bladder.Nat Rev Urol. 2013 Sep;10(9):513-21. doi: 10.1038/nrurol.2013.143. Epub 2013 Jul 2. Nat Rev Urol. 2013. PMID: 23817408 Review.
-
A comparison of sacral neuromodulation vs. transvaginal electrical stimulation for the treatment of refractory overactive bladder: the impact on quality of life, body image, sexual function, and emotional well-being.Prz Menopauzalny. 2019 Jun;18(2):89-93. doi: 10.5114/pm.2019.86834. Epub 2019 Jun 28. Prz Menopauzalny. 2019. PMID: 31485205 Free PMC article. Review.
-
Overactive bladder: strategies to ensure treatment compliance and adherence.Clin Interv Aging. 2016 Jun 3;11:755-60. doi: 10.2147/CIA.S69636. eCollection 2016. Clin Interv Aging. 2016. PMID: 27350744 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical